GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (FRA:4NX1) » Definitions » 10-Year ROIIC %

Lumos Pharma (FRA:4NX1) 10-Year ROIIC % : 212.12% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Lumos Pharma's 10-Year ROIIC % for the quarter that ended in Dec. 2023 was 212.12%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Lumos Pharma's 10-Year ROIIC % or its related term are showing as below:

FRA:4NX1's 10-Year ROIIC % is ranked better than
91.1% of 1359 companies
in the Biotechnology industry
Industry Median: -35.21 vs FRA:4NX1: 212.12

Lumos Pharma 10-Year ROIIC % Historical Data

The historical data trend for Lumos Pharma's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma 10-Year ROIIC % Chart

Lumos Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.97 53.98 141.75 420.94 212.12

Lumos Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 212.12 -

Competitive Comparison of Lumos Pharma's 10-Year ROIIC %

For the Biotechnology subindustry, Lumos Pharma's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumos Pharma's 10-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumos Pharma's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Lumos Pharma's 10-Year ROIIC % falls into.



Lumos Pharma 10-Year ROIIC % Calculation

Lumos Pharma's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -33.5447825 (Dec. 2023) - -22.8284786 (Dec. 2013) )/( 3.996 (Dec. 2023) - 5.008 (Dec. 2013) )
=-10.7163039/-1.012
=1,058.92%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Lumos Pharma  (FRA:4NX1) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Lumos Pharma 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Pharma (FRA:4NX1) Business Description

Traded in Other Exchanges
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

Lumos Pharma (FRA:4NX1) Headlines

No Headlines